risperidone has been researched along with ADDH in 112 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 9.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 9.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 9.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "A total of 168 children ages 6-12 with severe aggression (physical harm), DBD, and ADHD were randomized to parent training plus stimulant plus placebo (basic treatment) or parent training plus stimulant plus risperidone (augmented treatment) for 9 weeks." | 9.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 9.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| " The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested." | 9.19 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? ( Aman, MG; Arnold, LE; Austin, AB; Baker, J; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, H; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 9.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD." | 9.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 8.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 7.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| "The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone." | 7.74 | Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Lyoo, IK; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2007) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 7.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| "Risperidone was associated with a clinically significant global improvement, without seizure exacerbation in youths with epilepsy and psychiatric disorders." | 7.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 7.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 6.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Risperidone doses were low (0." | 6.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Priapism is the prolonged, painful erection of penile tissue not accompanied by sexual arousal." | 5.43 | Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. ( Baytunca, MB; Erermis, S; Kose, S; Ozbaran, B, 2016) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 5.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 5.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 5.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "A total of 168 children ages 6-12 with severe aggression (physical harm), DBD, and ADHD were randomized to parent training plus stimulant plus placebo (basic treatment) or parent training plus stimulant plus risperidone (augmented treatment) for 9 weeks." | 5.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 5.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| " The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested." | 5.19 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? ( Aman, MG; Arnold, LE; Austin, AB; Baker, J; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, H; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 5.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase." | 5.16 | Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012) |
| "Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD." | 5.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability." | 4.93 | Pharmacotherapy for mental health problems in people with intellectual disability. ( Findling, RL; Ji, NY, 2016) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| "This retrospective study delineated the efficacy of antiepileptic drugs in preventing the need for methylphenidate in patients with benign childhood epilepsy with centrotemporal spikes and attention deficit hyperactivity disorder." | 4.88 | Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder? ( Fattal-Valevski, A; Goldberg-Stern, H; Kramer, U; Schneebaum-Sender, N, 2012) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 4.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 3.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone." | 3.74 | Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Lyoo, IK; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2007) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 3.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| "Risperidone was associated with a clinically significant global improvement, without seizure exacerbation in youths with epilepsy and psychiatric disorders." | 3.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 3.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| "Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study); https://www." | 3.01 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. ( Bailey, BY; Blader, JC; Carlson, GA; Crowell, JA; Daviss, WB; Foley, CA; Kafantaris, V; Margulies, DM; Matthews, TL; Pliszka, SR; Sauder, C; Sinha, C, 2021) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 2.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Risperidone is safe and effective in treating DBDs in children over a cumulative period of 2 years." | 2.72 | Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. ( Augustyns, I; Croonenberghs, J; Eerdekens, M; Reyes, M, 2006) |
| "Risperidone-treated patients had clinically and statistically significant reductions in both disruptive behavior and hyperactivity subscale scores, compared to placebo, regardless of concomitant stimulant use." | 2.71 | Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. ( Aman, MG; Binder, C; Turgay, A, 2004) |
| "Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects." | 2.70 | Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. ( Bruggeman, R; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA; van der Linden, C, 2001) |
| "Risperidone doses were low (0." | 2.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Youth aggression is associated with complex genetic, neurobiological, and environmental risks." | 2.61 | Understanding Chronic Aggression and Its Treatment in Children and Adolescents. ( Magalotti, SR; McVoy, MK; Neudecker, M; Zaraa, SG, 2019) |
| "Risperidone has been used to treat ADHD in people with ID, although the evidence for its effectiveness is unclear." | 2.45 | Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. ( Maltezos, S; Paliokosta, E; Thomson, A; Xenitidis, K, 2009) |
| "We used a systematic survey to collate the consensus of Japanese experts and compare it with the recent international evidence." | 1.51 | Expert consensus on pharmacotherapy for tic disorders in Japan. ( Fujio, M; Hamamoto, Y; Kano, Y; Kono, T; Matsuda, N; Nonaka, M, 2019) |
| " The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended." | 1.48 | Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada. ( Cepoiu-Martin, M; Chen, W; Cooke, L; Duncan, D; Pringsheim, T; Stang, A; Symonds, C, 2018) |
| "Priapism is the prolonged, painful erection of penile tissue not accompanied by sexual arousal." | 1.43 | Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. ( Baytunca, MB; Erermis, S; Kose, S; Ozbaran, B, 2016) |
| ""B" was an 11-year-old girl with mild mental retardation and aggression who was treated with risperidone 1 mg per day." | 1.32 | Risperidone-induced obsessive-compulsive symptoms in two children. ( Avci, A; Diler, RS; Scahill, L; Yolga, A, 2003) |
| "The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder." | 1.29 | Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (8.93) | 18.2507 |
| 2000's | 41 (36.61) | 29.6817 |
| 2010's | 47 (41.96) | 24.3611 |
| 2020's | 14 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Roessner, V | 2 |
| Eichele, H | 1 |
| Stern, JS | 1 |
| Skov, L | 1 |
| Rizzo, R | 1 |
| Debes, NM | 1 |
| Nagy, P | 1 |
| Cavanna, AE | 2 |
| Termine, C | 1 |
| Ganos, C | 1 |
| Münchau, A | 2 |
| Szejko, N | 1 |
| Cath, D | 1 |
| Müller-Vahl, KR | 1 |
| Verdellen, C | 1 |
| Hartmann, A | 1 |
| Rothenberger, A | 1 |
| Hoekstra, PJ | 1 |
| Plessen, KJ | 1 |
| Siafis, S | 1 |
| Çıray, O | 1 |
| Wu, H | 1 |
| Schneider-Thoma, J | 1 |
| Bighelli, I | 1 |
| Krause, M | 1 |
| Rodolico, A | 1 |
| Ceraso, A | 1 |
| Deste, G | 1 |
| Huhn, M | 1 |
| Fraguas, D | 1 |
| San José Cáceres, A | 1 |
| Mavridis, D | 1 |
| Charman, T | 1 |
| Murphy, DG | 1 |
| Parellada, M | 2 |
| Arango, C | 2 |
| Leucht, S | 1 |
| Salazar de Pablo, G | 1 |
| Pastor Jordá, C | 1 |
| Vaquerizo-Serrano, J | 1 |
| Moreno, C | 1 |
| Cabras, A | 1 |
| Hernández, P | 1 |
| Veenstra-VanderWeele, J | 1 |
| Simonoff, E | 1 |
| Fusar-Poli, P | 1 |
| Santosh, P | 1 |
| Cortese, S | 2 |
| Baweja, R | 1 |
| Waxmonsky, JG | 1 |
| Eaton, C | 1 |
| Yong, K | 1 |
| Walter, V | 1 |
| Mbizvo, GK | 1 |
| Rhodes, S | 1 |
| Chin, RF | 1 |
| Naguy, A | 5 |
| Roshdy, R | 1 |
| Alamiri, B | 2 |
| Hashem, MS | 1 |
| AlKhadhar, S | 1 |
| Magalotti, SR | 1 |
| Neudecker, M | 1 |
| Zaraa, SG | 1 |
| McVoy, MK | 1 |
| Blader, JC | 2 |
| Pliszka, SR | 1 |
| Kafantaris, V | 1 |
| Foley, CA | 1 |
| Carlson, GA | 1 |
| Crowell, JA | 1 |
| Bailey, BY | 1 |
| Sauder, C | 1 |
| Daviss, WB | 1 |
| Sinha, C | 1 |
| Matthews, TL | 1 |
| Margulies, DM | 1 |
| Novins, DK | 1 |
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Burden, AM | 1 |
| Mosheva, M | 1 |
| Dar, N | 1 |
| Rima Madi, L | 1 |
| Weizman, A | 1 |
| Gothelf, D | 1 |
| Vaudreuil, C | 1 |
| Farrell, A | 1 |
| Wozniak, J | 3 |
| Rush Ortegon, E | 1 |
| Ferguson, J | 1 |
| Coffey, BJ | 1 |
| Binici, NC | 1 |
| Güney, SA | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Masi, G | 1 |
| Manfredi, A | 1 |
| Nieri, G | 1 |
| Muratori, P | 1 |
| Pfanner, C | 1 |
| Milone, A | 1 |
| Anagnostou, E | 1 |
| Chen, W | 1 |
| Cepoiu-Martin, M | 1 |
| Stang, A | 1 |
| Duncan, D | 1 |
| Symonds, C | 1 |
| Cooke, L | 1 |
| Pringsheim, T | 1 |
| Gnanavel, S | 2 |
| Joseph, HM | 1 |
| Farmer, C | 1 |
| Kipp, H | 5 |
| Kolko, D | 1 |
| Aman, M | 2 |
| McGinley, J | 1 |
| Arnold, LE | 10 |
| Gadow, KD | 9 |
| Findling, RL | 10 |
| Molina, BSG | 1 |
| Hamamoto, Y | 1 |
| Fujio, M | 1 |
| Nonaka, M | 1 |
| Matsuda, N | 1 |
| Kono, T | 1 |
| Kano, Y | 1 |
| Chovaz, CJ | 1 |
| Aman, MG | 9 |
| Bukstein, OG | 5 |
| Molina, BS | 6 |
| McNamara, NK | 6 |
| Rundberg-Rivera, EV | 5 |
| Li, X | 3 |
| Schneider, J | 4 |
| Butter, EM | 3 |
| Baker, J | 1 |
| Sprafkin, J | 2 |
| Rice, RR | 4 |
| Bangalore, SS | 3 |
| Farmer, CA | 7 |
| Austin, AB | 2 |
| Buchan-Page, KA | 4 |
| Brown, NV | 5 |
| Hurt, EA | 3 |
| Grondhuis, SN | 2 |
| Elbe, D | 1 |
| Barr, AM | 1 |
| Honer, WG | 1 |
| Procyshyn, RM | 1 |
| Javelot, H | 1 |
| Glay-Ribau, C | 1 |
| Ligier, F | 1 |
| Weiner, L | 1 |
| Didelot, N | 1 |
| Messaoudi, M | 1 |
| Socha, M | 1 |
| Body-Lawson, F | 1 |
| Kabuth, B | 1 |
| Jensen, PS | 1 |
| Kipp, HL | 1 |
| Baker, JL | 1 |
| Yorbik, O | 1 |
| Mutlu, C | 1 |
| Ozilhan, S | 1 |
| Eryilmaz, G | 1 |
| Isiten, N | 1 |
| Alparslan, S | 1 |
| Saglam, E | 1 |
| Kolko, DG | 1 |
| Bukstein, O | 2 |
| McNamara, N | 1 |
| Bangalore, S | 1 |
| Buchan-Page, K | 2 |
| Rice, R | 2 |
| Townsend, LD | 1 |
| Molina, BB | 1 |
| Kolko, DJ | 3 |
| Michel, C | 1 |
| Austin, A | 1 |
| Ince, E | 1 |
| Algedik, P | 1 |
| Demirdogen, ES | 1 |
| Emul, M | 1 |
| Demir, T | 1 |
| Koplewicz, HS | 1 |
| Baytunca, MB | 1 |
| Kose, S | 1 |
| Ozbaran, B | 1 |
| Erermis, S | 1 |
| Ji, NY | 1 |
| Accordino, RE | 1 |
| Kidd, C | 1 |
| Politte, LC | 1 |
| Henry, CA | 1 |
| McDougle, CJ | 4 |
| Calarge, CA | 2 |
| Murry, DJ | 1 |
| Ziegler, EE | 1 |
| Lamberti, M | 1 |
| Siracusano, R | 1 |
| Italiano, D | 1 |
| Alosi, N | 1 |
| Cucinotta, F | 1 |
| Di Rosa, G | 1 |
| Germanò, E | 1 |
| Spina, E | 1 |
| Gagliano, A | 1 |
| Epstein, JN | 1 |
| Butter, E | 1 |
| Grau, K | 1 |
| Plener, PL | 1 |
| Gahr, M | 1 |
| Denzer, C | 1 |
| Freudenmann, RW | 1 |
| Townsend, L | 1 |
| Gary, DS | 1 |
| Kaplin, DB | 1 |
| Williams, C | 1 |
| Jahangard, L | 1 |
| Akbarian, S | 1 |
| Haghighi, M | 1 |
| Ahmadpanah, M | 1 |
| Keshavarzi, A | 1 |
| Bajoghli, H | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Wadoo, O | 1 |
| Chalhoub, N | 1 |
| Goldstein, RB | 1 |
| Storch, EA | 1 |
| Lehmkuhl, H | 1 |
| Geffken, GR | 1 |
| Goodman, WK | 1 |
| Murphy, TK | 1 |
| Thomson, A | 1 |
| Maltezos, S | 1 |
| Paliokosta, E | 1 |
| Xenitidis, K | 1 |
| Monge Galindo, L | 1 |
| Escosa García, L | 1 |
| García Sánchez, N | 1 |
| Ruiz-Lázaro, PM | 1 |
| Amado, I | 1 |
| Bourdel, MC | 1 |
| Daban, C | 1 |
| Poirier, MF | 1 |
| Loo, H | 1 |
| Bouhours, P | 1 |
| Krebs, MO | 1 |
| Weiss, M | 1 |
| Panagiotopoulos, C | 1 |
| Giles, L | 1 |
| Gibbins, C | 1 |
| Kuzeljevic, B | 1 |
| Davidson, J | 1 |
| Harrison, R | 1 |
| Uchida, H | 1 |
| Rajji, TK | 1 |
| Mulsant, BH | 1 |
| Kapur, S | 1 |
| Pollock, BG | 1 |
| Graff-Guerrero, A | 1 |
| Menon, M | 1 |
| Mamo, DC | 1 |
| Bandou, N | 1 |
| Koike, K | 1 |
| Matuura, H | 1 |
| Carbray, MJ | 1 |
| McGuinness, T | 1 |
| Rothermel, B | 1 |
| Poustka, L | 2 |
| Banaschewski, T | 2 |
| Becker, K | 1 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Turner, CA | 1 |
| Xie, D | 1 |
| Zimmerman, BM | 1 |
| Hu, CH | 1 |
| Pai, N | 1 |
| Huang, XF | 1 |
| Deng, C | 1 |
| Holtmann, M | 1 |
| Rickards, H | 1 |
| Worrall, R | 1 |
| Schoenefeld, K | 1 |
| Buse, J | 1 |
| Bender, S | 1 |
| Ehrlich, S | 1 |
| Vitiello, B | 2 |
| Riddle, MA | 1 |
| Yenokyan, G | 1 |
| Axelson, DA | 1 |
| Wagner, KD | 1 |
| Joshi, P | 1 |
| Walkup, JT | 1 |
| Luby, J | 1 |
| Birmaher, B | 1 |
| Ryan, ND | 1 |
| Emslie, G | 1 |
| Robb, A | 1 |
| Tillman, R | 1 |
| Schneebaum-Sender, N | 1 |
| Goldberg-Stern, H | 1 |
| Fattal-Valevski, A | 1 |
| Kramer, U | 1 |
| Stern, AP | 1 |
| Trieu, ML | 1 |
| Kowatch, RA | 2 |
| Sethuraman, G | 1 |
| Hume, JH | 1 |
| Kromelis, M | 1 |
| Weinberg, WA | 1 |
| Diler, RS | 1 |
| Yolga, A | 1 |
| Avci, A | 1 |
| Scahill, L | 3 |
| Shintani, N | 1 |
| Tanaka, K | 1 |
| Hashimoto, H | 1 |
| Baba, A | 1 |
| Binder, C | 1 |
| Turgay, A | 1 |
| Gonzalez-Heydrich, J | 1 |
| Pandina, GJ | 1 |
| Fleisher, CA | 1 |
| Hsin, O | 1 |
| Raches, D | 1 |
| Bourgeois, BF | 1 |
| Biederman, J | 3 |
| Stein, MT | 1 |
| Faber, S | 1 |
| Berger, SP | 1 |
| Kliman, G | 1 |
| Bryois, C | 1 |
| Nanzer, N | 1 |
| Eliez, S | 1 |
| Etter, M | 1 |
| Aubry, JM | 1 |
| Bertschy, G | 1 |
| Benjamin, E | 1 |
| Salek, S | 1 |
| Correia Filho, AG | 1 |
| Bodanese, R | 1 |
| Silva, TL | 1 |
| Alvares, JP | 1 |
| Rohde, LA | 1 |
| Machida, N | 1 |
| Shiotsuka, S | 1 |
| Semba, J | 1 |
| Keenan, K | 1 |
| Pavuluri, MN | 1 |
| Schenkel, LS | 1 |
| Aryal, S | 1 |
| Harral, EM | 1 |
| Hill, SK | 1 |
| Herbener, ES | 1 |
| Sweeney, JA | 1 |
| Reyes, M | 1 |
| Croonenberghs, J | 1 |
| Augustyns, I | 1 |
| Eerdekens, M | 1 |
| Parraga, H | 1 |
| Harris, K | 1 |
| Moore, CM | 1 |
| Mick, E | 1 |
| Aleardi, M | 1 |
| Wardrop, M | 1 |
| Dougherty, M | 1 |
| Harpold, T | 1 |
| Hammerness, P | 1 |
| Randall, E | 1 |
| Lyoo, IK | 1 |
| Renshaw, PF | 1 |
| Günther, T | 1 |
| Herpertz-Dahlmann, B | 1 |
| Jolles, J | 1 |
| Konrad, K | 1 |
| Carlson, T | 1 |
| Reynolds, CA | 1 |
| Caplan, R | 1 |
| Sabuncuoglu, O | 1 |
| Armenteros, JL | 1 |
| Lewis, JE | 1 |
| Davalos, M | 1 |
| Sukhodolsky, DG | 1 |
| McCracken, JT | 1 |
| Tierney, E | 1 |
| Williams White, S | 1 |
| Lecavalier, L | 1 |
| Hollis, CP | 1 |
| Thompson, A | 1 |
| Niederhofer, H | 1 |
| Gleason, MM | 1 |
| Egger, HL | 1 |
| Emslie, GJ | 1 |
| Greenhill, LL | 1 |
| Lieberman, AF | 1 |
| Luby, JL | 1 |
| Owens, J | 1 |
| Scahill, LD | 1 |
| Scheeringa, MS | 1 |
| Stafford, B | 1 |
| Wise, B | 1 |
| Zeanah, CH | 1 |
| Barton, R | 1 |
| Willemsen, MA | 1 |
| van der Wal, KG | 1 |
| Keshen, A | 1 |
| Carandang, C | 1 |
| Sternlicht, HC | 1 |
| Wells, SR | 1 |
| Lombroso, PJ | 1 |
| King, RA | 1 |
| Lynch, KA | 1 |
| Chappell, PB | 1 |
| Peterson, BS | 1 |
| Leckman, JF | 1 |
| Wakefield, TP | 1 |
| Took, KJ | 1 |
| Buck, BJ | 1 |
| Feeney, DJ | 1 |
| Klykylo, W | 1 |
| Edleman, RJ | 1 |
| Steele, M | 1 |
| Fisman, S | 1 |
| Schreier, HA | 1 |
| Roberts, MD | 1 |
| Frazier, JA | 1 |
| Meyer, MC | 1 |
| Wilens, TE | 1 |
| Spencer, TJ | 1 |
| Kim, GS | 1 |
| Shapiro, S | 1 |
| Silver, H | 1 |
| Aharon, N | 1 |
| Schwartz, M | 1 |
| Lore, C | 1 |
| Bruggeman, R | 1 |
| van der Linden, C | 1 |
| Buitelaar, JK | 1 |
| Gericke, GS | 1 |
| Hawkridge, SM | 1 |
| Temlett, JA | 1 |
| Teoh, L | 1 |
| Allen, H | 1 |
| Kowalenko, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy[NCT00323947] | Phase 4 | 33 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Stimulant and Risperidone in Children With Severe Physical Aggression[NCT00796302] | Phase 4 | 168 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders[NCT02063945] | Phase 4 | 5 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to Major difficulties recruiting participants) | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antisocial Behavior Scale (ABS) is a 28-item scale that contains 10 Proactive Aggression items and six Reactive Aggression items. Each item is rated on a 3-point scale, ranging from 1 (Never) to 3 (Very often). Thus, scores on the Reactive Aggression subscale can range from 6 through 18; with higher scores indicating more reactive aggression. (NCT00796302)
Timeframe: Measured at baseline and Week 9
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 15.5 | 11.0 |
| Basic (Stimulant + PMT + Placebo) | 15.9 | 12.3 |
"Using this clinician rating scale the patient's improvement is scored on a 7-point scale which ranges from very much improved (1), through no change (4), to very much worse (7). This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Improvement scores are reported below." (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | ||
|---|---|---|---|
| Much or very much improved at endpoint | Minimally improved at endpoint | Unchanged or worse at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 63 | 11 | 6 |
| Basic (Stimulant + PMT + Placebo) | 58 | 22 | 3 |
Using this clinician rating scale the severity of the illness is scored from 1= normal to 7= extremely ill. This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Severity of Illness scores are reported below. (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | |
|---|---|---|
| Normal/Borderline/Mildly ill at endpoint | Moderately/Markedly/Severely ill at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 56 | 22 |
| Basic (Stimulant + PMT + Placebo) | 49 | 34 |
"Parent ratings of aggression and hostility on the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-Total Score. The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total.~For the NCBRF D-Total, higher scores reflect worse behavior. Each subscale is scored by taking the rating (0 [did not occur or was not a problem] to 3 [occurred a lot or was a very severe problem]) for all component items. The D-Total score was computed by adding the 6 scores from the Oppositional subscale and the 10 items from the Conduct Problem subscale. Thus D-Total scores could range from 0-69." (NCT00796302)
Timeframe: Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 42.1 | 25.9 | 17.1 | 12.1 | 13.8 | 13.0 | 11.7 | 10.7 |
| Basic (Stimulant + PMT + Placebo) | 43.5 | 24.9 | 22.4 | 20.1 | 20.7 | 16.8 | 17.8 | 17.8 |
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
21 reviews available for risperidone and ADDH
| Article | Year |
|---|---|
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Male; Rispe | 2022 |
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; H | 2022 |
Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2023 |
Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disor | 2022 |
Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2022 |
Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2019 |
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Topics: Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Comorbidity; Conduct Disor | 2021 |
Psychopharmacology of Treating Explosive Behavior.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
Psychopharmacological interventions in autism spectrum disorder.
Topics: Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Humans; Irrit | 2016 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Humans; Persons with Mental Disabilitie | 2009 |
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Dis | 2011 |
Pharmacological treatment of tic disorders and Tourette Syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2013 |
Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?
Topics: Age of Onset; Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Central Ner | 2012 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperacti | 2005 |
Psychopharmacological treatment for very young children: contexts and guidelines.
Topics: Algorithms; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; At | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; D | 2007 |
22 trials available for risperidone and ADDH
| Article | Year |
|---|---|
Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2017 |
Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2015 |
Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Topics: Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2015 |
Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Bone Density; Cal | 2016 |
Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2016 |
Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2017 |
The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2017 |
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical t
Topics: Adjuvants, Pharmaceutic; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2017 |
Preattentional processes and disorganization in schizophrenia: Influence of a 6-week risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Attention; Attention Deficit Disorder with Hypera | 2009 |
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study.
Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit | 2012 |
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde | 2003 |
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2004 |
Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2005 |
Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Co | 2006 |
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2007 |
Risperidone for young children with mood disorders and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; | 1998 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
69 other studies available for risperidone and ADDH
| Article | Year |
|---|---|
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Child; Conduct Disorder; Humans; Pancr | 2022 |
Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
Topics: Aggression; Antidepressive Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2020 |
Methylphenidate-Induced Persistent Hiccups in a Child With ADHD Relieved by Add-On Risperidone.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Hiccup; Hum | 2020 |
A Prepubertal Girl with Delusions of Pregnancy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delusions; Female; Humans; Hyperprolactinemia; | 2021 |
ADHD Masquerading as Cautopyreiophagia Exacerbated by Risperidone and Improved With Methylphenidate in a Preschooler.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2021 |
Epistaxis as an Unexpected Side Effect of Aripiprazole and Risperidone Treatment in Two Children with Two Different Psychiatric Diagnosis.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spect | 2017 |
Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada.
Topics: Adolescent; Alberta; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chi | 2018 |
Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2018 |
Expert consensus on pharmacotherapy for tic disorders in Japan.
Topics: Adult; Aged; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Comorbidity; Consensus; Dr | 2019 |
Report of a deaf child with Tourette's disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Female; Humans; Language Development; Par | 2013 |
Not just another antipsychotic-for-conduct-problems trial.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Smith-Magneis syndrome: behavioural phenotype mimics ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 2014 |
Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2014 |
Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Conduct Disorder | 2014 |
TOSCA: no longer just an opera.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
Topics: Administration, Oral; Adolescent; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Centr | 2015 |
The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2015 |
From the Editor-in-Chief's Desk.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nerv | 2015 |
Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chlorpromazine; Dru | 2016 |
Mild Hypothermia in a Child with Low-Dose Risperidone.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb | 2017 |
Risperidone-induced sexual dysfunction in a prepubertal child - a case report.
Topics: Aggression; Anger; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Human | 2009 |
Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Dis | 2009 |
[Hyperprolactinemia in a child diagnosed with Asperger syndrome and hyperkinetic disorder treated with risperidone].
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Child, Presc | 2009 |
A washout period needed before switching from a neuroleptic to an amphetamine.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child | 2009 |
A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2009 |
D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia.
Topics: Age of Onset; Aged; Attention Deficit Disorder with Hyperactivity; Cross-Sectional Studies; Dopamine | 2009 |
Predictive familial risk factors and pharmacological responses in ADHD with comorbid disruptive behavior disorders.
Topics: Adolescent; Age Distribution; Analysis of Variance; Attention Deficit and Disruptive Behavior Disord | 2010 |
Pediatric bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder wi | 2009 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Iron status in toddlerhood predicts sensitivity to psychostimulants in children.
Topics: Anemia, Iron-Deficiency; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Centra | 2012 |
Potential control of risperidone-related cognitive deficits by adjunctive aripiprazole treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Antagonists; Dopamine D2 Receptor Antagonist | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2012 |
Risperidone-induced obsessive-compulsive symptoms in two children.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Female; Huma | 2003 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Model | 2003 |
No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; | 2004 |
International adoption: a four-year-old child with unusual behaviors adopted at six months of age.
Topics: Adoption; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child Behavior Disorders | 2004 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
Stimulant-atypical antipsychotic interaction and acute dystonia.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar | 2005 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
Antipsychotics in disruptive behavior disorders and ADHD.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2005 |
Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Catatonia under treatment with risperidone.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Catatonia; Child; Child Behavio | 2006 |
Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; C | 2007 |
The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Attention Deficit and Disruptive Behavior D | 2006 |
Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Bipolar Diso | 2007 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Topics: Acute Disease; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2007 |
Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).
Topics: Abnormalities, Multiple; Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder wi | 2007 |
[Medication-induced mandibular luxation in a seven-year-old patient].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Dystonia; Humans; | 2008 |
Acute dystonic reaction in an adolescent on risperidone when a concomitant stimulant medication is discontinued.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2007 |
Risperidone in childhood schizophrenia.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combinatio | 1995 |
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise | 1995 |
The combined pharmacotherapy controversy.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chil | 1996 |
Enuresis with combined risperidone and SSRI use.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1996 |
Risperidone and tardive dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder | 1996 |
TD from risperidone?
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dyskinesia, Drug-In | 1997 |
Bipolar disorder in children and adolescents: current challenges.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Clom | 1997 |
Risperdal and parkinsonian tremor.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; C | 1999 |
Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dyskinesia, Drug-Induced | 2000 |
Risperidone and withdrawal dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dibenzothiazepines; | 2000 |
Drug-induced extrapyramidal reactions.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Child; | 2002 |